Endogenous CD8+ T cell expansion during regression of monoclonal EBV- associated posttransplant lymphoproliferative disorder

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 500-506

  Khatri, Vijay P ^a   Baiocchi, Robert A ^b   Peng, Ruoqi ^b   Oberkircher, Adam R ^a   Dolce, Jean M ^a   Ward, Pamela M ^a   Herzig, Geoffrey P ^b   Caligiuri, Michael A ^b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOLYSIS; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS TRANSFORMATION;

ADULT; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL DIVISION; CLONE CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE REARRANGEMENT, BETA-CHAIN T-CELL ANTIGEN RECEPTOR; HERPESVIRUS 4, HUMAN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033168702     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405.
2. Baiocchi, R. A., and M. A. Caligiuri. 1994. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 91:5577.
3. Lacerda, J. F., M. Ladanyi, D. C. Louie, J. M. Fernandez, E. B. Papadopoulos, and R. J. O'Reilly. 1996. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted CB-17 scid/scid mice. J. Exp. Med. 183:1215.
4. Purtillo, D. T., R. S. Strobach, M. Okano, and J. Davis. 1992. Biology of disease: Epstein-Barr virus associated lymphoproliferative disease. Lab. Infest. 67:5.
5. Knowles, D. M., E. Cesarman, A. Chadburn, G. Frizzera, J. Chen, E. A. Rose, and R. E. Michler. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552.
6. Hanto, D. W. 1995. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu. Rev. Med. 46:381.
7. Starzl, T. E., M. A. Nalesnik, K. A. Porter, M. Ho, S. Iwatsuki, B. P. Griffith, J. T. Rosenthal, T. R. Hakala, B. W. Shaw, Jr., R. L. Hardesty, et al. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583.
8. Seiden, M. V., and J. Sklar. 1993. Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol. Oncol. Clin. North Am. 7:447.
9. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
10. Ravetch, J. V., U. Siebenlist, S. Korsmeyer, T. Waldmann, and P. Leder. 1981. Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell 27:583.
11. Rickinson, A. B., Lee, S. P., and Steven, N. M. 1996. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr. Opin. Immunol. 8:492.
12. Stewart, C. C., and S. J. Stewart. 1995. Cell Preparation for the Identification of Leukocytes. Academic Press, New York.
13. Yates, J., N. Warren, D. Reisman, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA 81:3806.
14. Cossman, J., B. Zehnbauer, C. T. Garrett, L. J. Smith, M. Williams, E. S. Jaffe, L. O. Hanson, and J. Love. 1991. Gene rearrangements in the diagnosis of lymphoma/leukemia. Guidelines for use based on a multiinstitutional study. Am. J. Clin. Pathol. 95:347.
15. Greenberg, S. J., Y. Choi, M. Ballow, T. L. Du, P. M. Ward, M. H. Rickert, S. Frankel, S. H. Bernstein, and M. L. Brecher. 1995. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia. J. Leukocyte Biol. 57:856.
16. Oberkircher, A. R., M. P. Strout, G. P. Herzig, P. D. Fritz, and M. A. Caligiuri. 1995. Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation. Bone Marrow Transplant. 16:695.
17. Caligiuri, M. A., A. Zmuidzinas, T. J. Manley, H. Levine, K. A. Smith, and J. Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171:1509.
18. Teo, C. G., and B. E. Griffin. 1987. Epstein-Barr virus genomes in lymphoid cells: activation in mitosis and chromosomal location. Proc. Natl. Acad. Sci. USA 84:8473.
19. Miller, W. E., R. H. Edwards, D. M. Walling, and N. Raab-Traub. 1994. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 75:2729.
20. Bragado, R., P. Lauzurica, D. Lopez, and J. A. Lopez de Castro. 1990. T cell receptor Vβ gene usage in a human alloreactive response. J. Exp. Med. 171:1189.
21. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173.
22. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150.
23. Ko, H. S., S. M. Fu, R. J. Winchester, D. T. Y. Yu, and H. G. Kunkel. 1979. Ia determinants on stimulated human T lymphocytes: occurrence on mitogen- and antigen-activated cells. J. Exp. Med. 150:246.
24. Boitel, B., M. Ermonval, P. Panina-Bordignon, R. A. Mariuzza, A. Lanzavecchia, and O. Acuto. 1992. Preferential Vβ gene usage and lack of junctional sequence conservation among human T cell receptors specific for a tetanus toxin-derived peptide: evidence for a dominant role of a germline-encoded V region in antigen/ major histocompatibility complex recognition. J. Exp. Med. 175:765.
25. Dietrich, P. Y., A. Caignard, A. Diu, C. Genevee, J. L. Pico, M. Henry-Amar, J. Bosq, E. Angevin, F. Triebel, and T. Hercend. 1992. Analysis of T-cell receptor variability in transplanted patients with acute graft-versus-host disease. Blood 80:2419.
26. Masuko, K., S. Kato, M. Hagihara, F. Tsuchida, Y. Takemoto, K. Izawa, T. Kato, S. Yamamori, Y. Mizushima, K. Nishioka, et al. 1996. Stable clonal expansion of T cells induced by bone marrow transplantation. Blood 87:789.
27. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157.
28. Slobod, K. S., A. S. Freiberg, J. E. Allan, S. D. Rencher, and J. L. Hurwitz. 1993. T-cell receptor heterogeneity among Epstein-Barr virus-stimulated T-cell populations. Virology 196:179.
29. + T cells in acute infectious mononucleosis. Nat. Med. 2:906.
30. Steven, N., A. M. Leese, N. E. Annels, S. P. Lee, and A. B. Rickinson. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184:1801.
31. Silins, S. L., S. M. Cross, K. G. Krauer, D. J. Moss, C. W. Schmidt, and I. S. Misko. 1998. A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J. Clin. Invest. 102:1551.
32. Wallace, L. E., D. J. Moss, A. B. Rickinson, A. J. McMichael, and M. A. Epstein. 1981. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. Eur. J. Immunol. 11:694.
33. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739.
34. Caldwell, R. G., J. B. Wilson, S. J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405.
35. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccina: implications for vaccine development. J. Exp. Med. 176:169.
36. Lucas, K. G., T. N. Small, G. Heller, B. Dupont, R. J. O'Reilly. 1996. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87:2594.
37. Babcock, G. I., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity 9:395.
38. MacLennan, I. C. 1994. Germinal centers. Annu. Rev. Immunol. 12:117.
39. Liu, Y. J., C. Arpin, O. de Boouteiller, C. Guret, J. Banchereau, H. Martiner-Valdez, and S. Lebecque. 1996. Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Semin. Immunol. 8:169.
40. Polack, A., K. Hortnagel, A. Pajic, B. Christoph, B. Baier, M. Falk, J. Mautner, C. Geltinger, G. W. Bornkamm, and B. Kempkes. 1996. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. USA 93:10411.
41. Ferrara, J. L., and H. J. Deeg. 1991. Graft-versus-host disease. N. Engl. J. Med. 324:667.
42. Schendel, D. J., C. Reinhardt, P. J. Nelson, B. Maget, L. Pullen, G. W. Bornkamm, and A. Steinle. 1992. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J. Immunol. 149:2406.
43. Rooney, C. M., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9.